Tissue-engineered Vascular Grafts for Congenital Cardiac Disease: Clinical Experience and Current Status

Overview

Journal Trends Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2017 Jul 30

PMID 28754230

Citations 28

Authors

Joseph D Drews

Hideki Miyachi

Toshiharu Shinoka

Affiliations

Soon will be listed here.

Abstract

Congenital heart disease is a leading cause of death in the newborn period, and man-made grafts currently used for reconstruction are associated with multiple complications. Tissue engineering can provide an alternative source of vascular tissue in congenital cardiac surgery. Clinical trials have been successful overall, but the most frequent complication is graft stenosis. Recent studies in animal models have indicated the important role of the recipient׳s immune response in neotissue formation, and that modulating the immune response can reduce the incidence of stenosis.

Citing Articles

Recent Advances in Hydrogel-Based 3D Bioprinting and Its Potential Application in the Treatment of Congenital Heart Disease.

Salih T, Caputo M, Ghorbel M Biomolecules. 2024; 14(7).

PMID: 39062575 PMC: 11274841. DOI: 10.3390/biom14070861.

Strategies to counteract adverse remodeling of vascular graft: A 3D view of current graft innovations.

Tan W, Boodagh P, Selvakumar P, Keyser S Front Bioeng Biotechnol. 2023; 10:1097334.

PMID: 36704297 PMC: 9871289. DOI: 10.3389/fbioe.2022.1097334.

Evaluation of personalized right ventricle to pulmonary artery conduits using in silico design and computational analysis of flow.

Ebrahimi P, Youssef D, Salve G, Ayer J, Dehghani F, Fletcher D JTCVS Open. 2022; 1:33-48.

PMID: 36003197 PMC: 9390144. DOI: 10.1016/j.xjon.2020.02.002.

Bioengineering Human Tissues and the Future of Vascular Replacement.

Naegeli K, Kural M, Li Y, Wang J, Hugentobler E, Niklason L Circ Res. 2022; 131(1):109-126.

PMID: 35737757 PMC: 9213087. DOI: 10.1161/CIRCRESAHA.121.319984.

Tissue engineered vascular grafts transform into autologous neovessels capable of native function and growth.

Blum K, Zbinden J, Ramachandra A, Lindsey S, Szafron J, Reinhardt J Commun Med (Lond). 2022; 2:3.

PMID: 35603301 PMC: 9053249. DOI: 10.1038/s43856-021-00063-7.

References

Roh J, Sawh-Martinez R, Brennan M, Jay S, Devine L, Rao D . Tissue-engineered vascular grafts transform into mature blood vessels via an inflammation-mediated process of vascular remodeling. Proc Natl Acad Sci U S A. 2010; 107(10):4669-74. PMC: 2842056. DOI: 10.1073/pnas.0911465107. View

Giannico S, Hammad F, Amodeo A, Michielon G, Drago F, Turchetta A . Clinical outcome of 193 extracardiac Fontan patients: the first 15 years. J Am Coll Cardiol. 2006; 47(10):2065-73. DOI: 10.1016/j.jacc.2005.12.065. View

Fukunishi T, Best C, Sugiura T, Opfermann J, Ong C, Shinoka T . Preclinical study of patient-specific cell-free nanofiber tissue-engineered vascular grafts using 3-dimensional printing in a sheep model. J Thorac Cardiovasc Surg. 2016; 153(4):924-932. PMC: 5715716. DOI: 10.1016/j.jtcvs.2016.10.066. View

Walles T, Gorler H, Puschmann C, Mertsching H . Functional neointima characterization of vascular prostheses in human. Ann Thorac Surg. 2004; 77(3):864-8. DOI: 10.1016/j.athoracsur.2003.08.048. View

Shinoka T, Shum-Tim D, Ma P, Tanel R, Isogai N, Langer R . Creation of viable pulmonary artery autografts through tissue engineering. J Thorac Cardiovasc Surg. 1998; 115(3):536-45; discussion 545-6. DOI: 10.1016/S0022-5223(98)70315-0. View

Simon P, Kasimir M, Seebacher G, Weigel G, Ullrich R, Salzer-Muhar U . Early failure of the tissue engineered porcine heart valve SYNERGRAFT in pediatric patients. Eur J Cardiothorac Surg. 2003; 23(6):1002-6; discussion 1006. DOI: 10.1016/s1010-7940(03)00094-0. View

Rosenman J, Kempczinski R, Pearce W, Silberstein E . Kinetics of endothelial cell seeding. J Vasc Surg. 1985; 2(6):778-84. View

Preis M, Schneiderman J, Koren B, Ben-Yosef Y, Levin-Ashkenazi D, Shapiro S . Co-expression of fibulin-5 and VEGF165 increases long-term patency of synthetic vascular grafts seeded with autologous endothelial cells. Gene Ther. 2015; 23(3):237-46. DOI: 10.1038/gt.2015.104. View

FONTAN F, Baudet E . Surgical repair of tricuspid atresia. Thorax. 1971; 26(3):240-8. PMC: 1019078. DOI: 10.1136/thx.26.3.240. View

10.

Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M . Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res. 1999; 85(3):221-8. DOI: 10.1161/01.res.85.3.221. View

11.

Shinoka T, Matsumura G, Hibino N, Naito Y, Watanabe M, Konuma T . Midterm clinical result of tissue-engineered vascular autografts seeded with autologous bone marrow cells. J Thorac Cardiovasc Surg. 2005; 129(6):1330-8. DOI: 10.1016/j.jtcvs.2004.12.047. View

12.

Jonas R, Freed M, Mayer Jr J, Castaneda A . Long-term follow-up of patients with synthetic right heart conduits. Circulation. 1985; 72(3 Pt 2):II77-83. View

13.

Hibino N, Yi T, Duncan D, Rathore A, Dean E, Naito Y . A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts. FASEB J. 2011; 25(12):4253-63. PMC: 3236622. DOI: 10.1096/fj.11-186585. View

14.

Villalona G, Udelsman B, Duncan D, McGillicuddy E, Sawh-Martinez R, Hibino N . Cell-seeding techniques in vascular tissue engineering. Tissue Eng Part B Rev. 2010; 16(3):341-50. PMC: 2946885. DOI: 10.1089/ten.TEB.2009.0527. View

15.

Brennan M, Dardik A, Hibino N, Roh J, Nelson G, Papademitris X . Tissue-engineered vascular grafts demonstrate evidence of growth and development when implanted in a juvenile animal model. Ann Surg. 2008; 248(3):370-7. PMC: 2726802. DOI: 10.1097/SLA.0b013e318184dcbd. View

16.

Matsumura G, Hibino N, Ikada Y, Kurosawa H, Shinoka T . Successful application of tissue engineered vascular autografts: clinical experience. Biomaterials. 2003; 24(13):2303-8. DOI: 10.1016/s0142-9612(03)00043-7. View

17.

Homann M, Haehnel J, Mendler N, Paek S, Holper K, Meisner H . Reconstruction of the RVOT with valved biological conduits: 25 years experience with allografts and xenografts. Eur J Cardiothorac Surg. 2000; 17(6):624-30. DOI: 10.1016/s1010-7940(00)00414-0. View

18.

Dahl S, Kypson A, Lawson J, Blum J, Strader J, Li Y . Readily available tissue-engineered vascular grafts. Sci Transl Med. 2011; 3(68):68ra9. DOI: 10.1126/scitranslmed.3001426. View

19.

Zhang J, Qi H, Wang H, Hu P, Ou L, Guo S . Engineering of vascular grafts with genetically modified bone marrow mesenchymal stem cells on poly (propylene carbonate) graft. Artif Organs. 2006; 30(12):898-905. DOI: 10.1111/j.1525-1594.2006.00322.x. View

20.

Hibino N, Nalbandian A, Devine L, Martinez R, McGillicuddy E, Yi T . Comparison of human bone marrow mononuclear cell isolation methods for creating tissue-engineered vascular grafts: novel filter system versus traditional density centrifugation method. Tissue Eng Part C Methods. 2011; 17(10):993-8. PMC: 3182675. DOI: 10.1089/ten.TEC.2011.0110. View